A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
NCT ID: NCT03336619
Last Updated: 2022-06-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1030 participants
INTERVENTIONAL
2018-01-17
2019-04-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
NCT02612922
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
NCT01610245
Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza
NCT01056380
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
NCT01227421
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
NCT03605862
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nitazoxanide
Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
Nitazoxanide
Nitazoxanide 600 mg administered orally twice daily for five days
Placebo
Two Placebo tablets orally twice daily (b.i.d.) for 5 days
Placebo
Placebo administered orally twice daily for five days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nitazoxanide
Nitazoxanide 600 mg administered orally twice daily for five days
Placebo
Placebo administered orally twice daily for five days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Presence of clinical signs and/or symptoms consistent with an acute illness compatible with influenza infection (each of the following is required):
1. oral temperature ≥99.4°F or ≥37.4°C (obtained in office or self- measured within 12 hours prior to screening - if self-measured, subjects must also have taken an antipyretic within 4 hours prior to screening), AND
2. at least one of the following respiratory symptoms (cough, sore throat, nasal obstruction), AND
3. one of the following constitutional symptoms (fatigue, headache, myalgia, feverishness).
3. Confirmation of influenza A or B infection in the local community by one of the following means:
1. the institution's local laboratory,
2. the local public health system,
3. the national public health system, OR
4. a laboratory of a recognized national or multinational influenza surveillance scheme.
4. Onset of illness no more than 40 hours before enrollment in the trial.
Note: Time of onset of illness is defined as either the earlier of:
1. the time when the temperature was first measured as elevated, OR
2. the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.
5. Willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of the patient diary.
Exclusion Criteria
2. Moderate or severe persistent asthma.
3. Cystic fibrosis in children.
4. Stage III or IV (severe or very severe) chronic obstructive pulmonary disease (COPD).
5. Class III or IV congestive heart failure (at least marked limitation of physical activity in which minimal ordinary activity results in fatigue, palpitation, dyspnea, or angina pain)
6. Arrhythmia
7. Immunosuppressive disorders or who are receiving immunosuppressive therapy (e.g., for organ or bone marrow transplants)
8. Untreated HIV infection or treated HIV infection with a CD4 count below 350 cells/mm3 in the last 6 months
9. Persons with sickle cell anemia or other hemoglobinopathies
10. Poorly controlled insulin-dependent diabetes mellitus (HBA1C \> 8%)
11. Residents of any age of nursing homes or other long-term care institutions
12. Concurrent infection at the screening examination that requires systemic antimicrobial therapy.
13. Females of childbearing potential who are either pregnant, breast-feeding or are sexually active without the use of birth control. Female subjects of child-bearing potential that are sexually active must have a negative baseline pregnancy test and must agree to continue an acceptable method of birth control for the duration of the study and for 1 month post- treatment. A double barrier method, oral birth control pills administered for at least 2 monthly cycles prior to study drug administration, an IUD, or medroxyprogesterone acetate administered intramuscularly for a minimum of one month prior to study drug administration are acceptable methods of birth control for inclusion into the study. Female subjects are considered of childbearing potential unless they are postmenopausal (absence of menstrual bleeding for 1 year - or 6 months if laboratory confirmation of hormonal status), or have had a hysterectomy, bilateral tubular ligation or bilateral oophorectomy.
14. Receipt of any dose of NTZ, oseltamivir, zanamivir, peramivir, laninamivir, baloxavir, amantadine or rimantadine within 3 days prior to screening.
15. Prior treatment with any investigational drug therapy within 30 days prior to screening.
16. Subjects with active respiratory allergies or subjects expected to require anti-allergy medications during the study period for respiratory allergies.
17. Known sensitivity to NTZ or any of the excipients comprising the NTZ tablets.
18. Subjects unable to take oral medications.
19. Presence of any pre-existing illness that, in the opinion of the Investigator, would place the subject at an unreasonably increased risk through participation in this study.
20. Subjects who, in the judgment of the Investigator, will be unlikely to comply with the requirements of this protocol.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Romark Laboratories L.C.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Francois Rossignol, M.D., Ph.D.
Role: STUDY_DIRECTOR
Romark Laboratories L.C.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanguard Study Site
Alabaster, Alabama, United States
Vanguard Study Site
Birmingham, Alabama, United States
Vanguard Study Site
Birmingham, Alabama, United States
Vanguard Study Site
Hoover, Alabama, United States
Vanguard Study Site
Pelham, Alabama, United States
Vanguard Study Site
Goodyear, Arizona, United States
Vanguard Study Site
Tolleson, Arizona, United States
Vanguard Study Site
Hot Springs, Arkansas, United States
Vanguard Study Site
Anaheim, California, United States
Vanguard Study Site
Westminster, California, United States
Vanguard Study Site
Lauderdale Lakes, Florida, United States
Vanguard Study Site
Orlando, Florida, United States
Vanguard Study Site
Valparaiso, Indiana, United States
Vanguard Study Site
New Orleans, Louisiana, United States
Vanguard Study Site
St Louis, Missouri, United States
Vanguard Study Site
Missoula, Montana, United States
Vanguard Study Site
Brooklyn, New York, United States
Vanguard Study Site
Cincinnati, Ohio, United States
Vanguard Study Site
Columbus, Ohio, United States
Vanguard Study Site
Dayton, Ohio, United States
Vanguard Study Site
Medford, Oregon, United States
Vanguard Study Site
Rapid City, South Dakota, United States
Vanguard Study Site
Jackson, Tennessee, United States
Vanguard Study Site
Smyrna, Tennessee, United States
Vanguard Study Site
Austin, Texas, United States
Vanguard Study Site
Carrollton, Texas, United States
Vanguard Study Site
Dallas, Texas, United States
Vanguard Study Site
Dallas, Texas, United States
Vanguard Study Site
Fort Worth, Texas, United States
Vanguard Study Site
Houston, Texas, United States
Vanguard Study Site
Pharr, Texas, United States
Vanguard Study Site
Plano, Texas, United States
Vanguard Study Site
Plano, Texas, United States
Vanguard Study Site
St. George, Utah, United States
Vanguard Study Site
Morayfield, Queensland, Australia
Vanguard Study Site
Sherwood, Queensland, Australia
Vanguard Study Site
Victoria Point, Queensland, Australia
Vanguard Study Site
Ponce, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RM08-3004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.